What's in Promomed, LLC's pipeline?

Promomed, LLC has 5 drugs in our index: 3 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Promomed, LLC's portfolio?

Top competitors by shared drug class: Assistance Publique - Hôpitaux de Paris, Estetra, French National Agency for Research on AIDS and Viral Hepatitis, Göteborg University, Hoffmann-La Roche.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/promomed-llc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Promomed, LLC — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Promomed, LLC pipeline: 3 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
sibutramine+ microcrystalline cellulose	sibutramine+ microcrystalline cellulose	marketed	Sympathomimetic amine; appetite suppressant	Norepinephrine transporter (NET), serotonin transporter (SERT), dopamine transporter (DAT)	Obesity; Weight management
metformin+sibutramine	metformin+sibutramine	marketed	Antidiabetic agent + appetite suppressant combination	AMP-activated protein kinase (metformin); serotonin and norepinephrine transporters (sibutramine)	Endocrinology / Diabetes
Ethyl methyl hydroxypyridine succinate + Meldonium	Ethyl methyl hydroxypyridine succinate + Meldonium	marketed	Antioxidant/metabolic enhancer combination		Cardiovascular, Neurology
Double-Stranded RNA sodium salt	Double-Stranded RNA sodium salt	phase 3	Toll-like receptor agonist / Immunostimulant	TLR3 (Toll-like receptor 3)	Oncology
Molnupiravir (Esperavir)	Molnupiravir (Esperavir)	phase 3	Nucleoside analog antiviral	Viral RNA-dependent RNA polymerase	Infectious Disease / Virology

Therapeutic area mix

Cardiovascular, Neurology · 1
Endocrinology / Diabetes · 1
Infectious Disease / Virology · 1
Obesity; Weight management · 1
Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Estetra · 1 shared drug class
French National Agency for Research on AIDS and Viral Hepatitis · 1 shared drug class
Göteborg University · 1 shared drug class
Hoffmann-La Roche · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
MinaPharm Pharmaceuticals · 1 shared drug class
Ain Shams University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Promomed, LLC:

Cite this brief

Drug Landscape (2026). Promomed, LLC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/promomed-llc. Accessed 2026-06-10.